Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Archief voor de categorie ‘Wet- en regelgeving’

U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds

As if Johnson & Johnson didn’t have enough legal woes already, with the mounting number of cases claiming a link between its talcum powder and ovarian cancer, the pharma giant now faces a fresh round of investigations into its marketing practices.

Bron: FiercePharma Meer lezen »

Novo Nordisk reaches whistleblower settlement in ‘white-coat’ sales scheme lawsuit

Novo Nordisk has moved to settle a whistleblower lawsuit alleging the company ran a “white-coat marketing scheme” to pump up sales of NovoLog, Victoza and Levemir. According to the suit —recently unsealed as part of the settlement process—Novo Nordisk partnered with a clinical education company, Healthstar’s PT, to set up a program dubbed Changing Life with […]

Bron: FiercePharma Meer lezen »

Can UK pharma rise to the post-Brexit challenge?

The UK life science sector contributed over £30bn to the UK economy in 2015. UK pharma invests £11.5m per day on research and development, which represents 25% of total research and development expenditure across all UK businesses. Will Brexit arrive with a worrying dose of reality?

Bron: PMLiVE Meer lezen »

Republicans forge ahead on Obamacare repeal despite U.S. budget worries

Republicans pushed ahead on Thursday with their plan for a massive overhaul of the U.S. healthcare system backed by President Donald Trump, despite Democratic concern that the cost of the bill and its impact on the budget remain unknown.

Bron: Reuters Meer lezen »

Interview – Dr. Henk Jan Out: “Wees transparant als farmamarketeer en leg zaken beter uit”

Dr. Henk Jan Out“Leve het geneesmiddel!”, het boek van dr. Henk Jan Out, voormalig bijzonder hoogleraar farmaceutische geneeskunde aan het Radboudumc, creëerde veel reuring in offline en online media afgelopen tijd. Met deze aandacht, zowel negatief als positief, probeert hij het beeld van de farmaceutische industrie bij ‘vooringenomen’ critici te veranderen. “Ik zou graag willen dat mensen genuanceerder nadenken over wat de industrie precies doet en hoe zorgvuldig ze dat doet.”

Meer lezen »

  Meer lezen »

Farmaceut Mylan verlaagt medicijnprijzen na kritiek

De Amerikaanse farmaceut Mylan halveert de prijs van een van zijn medicijnen na forse kritiek op prijsstijgingen. Dat maakte het statutair in Nederland gevestigde bedrijf, met hoofdkantoor in het Britse Hertfordshire, donderdag bekend.

Bron: Skipr Meer lezen »

Former shareholders sue Valeant, alleging “vast fraud”

Valeant Pharmaceuticals has confirmed that it is being sued by one its former largest shareholders, T Rowe Price, who claim that the company used deceptive measures to mislead shareholders and inflate sales figures.

Bron: InPharm.com Meer lezen »

Nice backs UCB’s Cimzia as alternate therapy for severe rheumatoid arthritis

The National Institute for Health and Care Excellence (Nice) has recommended UCB Pharma’s Cimzia (certolizumab pegol) on its own or in combination with methotrexate, to treat rheumatoid arthritis when other drugs haven’t worked or aren’t suitable.  

Bron: InPharm.com Meer lezen »

FDA panel backs Amgen copy of AbbVie arthritis drug Humira

 Amgen Inc’s cheaper version of AbbVie’s top-selling arthritis drug Humira is highly similar to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday.

Bron: Reuters Meer lezen »

Shire dry eye treatment gets FDA approval

Shire (LSE: SHP) has announced that the US Food and Drug Administration has approved its twice-daily eye drop solution, Xiidra (lifitegrast) for the treatment of the signs and symptoms of dry eye disease in adult patients.  

Bron: InPharm.com Meer lezen »

« Oudere artikelen |